SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company developing fully human polyclonal antibody therapeutics using a proprietary platform centered on genetically engineered cattle. The company entered the public markets through a merger with Big Rock Partners Acquisition Corp, a blank-check company sponsored by Big Rock Partners, with the de-SPAC transaction closing in October 2021. SAB Biotherapeutics operates within the biotechnology sector, with pipeline candidates targeting infectious disease and immunology indications. The S-1/A amendment filed January 4, 2021 represents an early registration step associated with that transaction. Sign up on SpacDesk for full filings history, deal analytics, and real-time data on SABS and hundreds of other SPAC transactions.